Thursday, November 14, 2013
set up its adverse event database decades ago to capture the side effects of
marketed drugs, but a group from the Icahn School of Medicine at Mount Sinai has now
exploited the millions of entries to extract a different type of information-beneficial
drug combinations that statistically reduce a drug's risk of toxicity. The
positive interactions could reveal nodes at which pathways intersect, providing
new targets to help guide drug discovery.
C.S. SciBX 6(44);
Published online Nov. 14, 2013
1. Zhao, S. et al. Sci.
Transl. Med.; published online Oct. 9, 2013;
Contact: Ravi Iyengar, Icahn School of Medicine at Mount Sinai, New
AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Bristol-Myers Squibb Co. (NYSE:BMY),
New York, N.Y.
Food and Drug Administration, Silver Spring, Md.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Icahn School of Medicine at Mount Sinai, New York, N.Y.
Systems Biology Center New York, New York, N.Y.